dupilumab
regeneron,sanofi
['dupixent', 'dupilumab', '$regn']
dupixent (dupilumab) late-breaking phase 3 data at the eadv 2022 congress showed significant improvements in signs and symptoms of prurigo nodularis $regn 
Real-Time News, Market Data and Stock Quotes For Green Stocks @ https://t.co/70sW9CbveB